A Message from Jim: Welcome to Laboratory Business Insights, a complimentary newsletter focused on the operational, financial, and technology challenges facing today’s laboratory industry. After four decades working in laboratory billing, collections, revenue cycle management, and LIS implementation, I’ve seen our industry evolve from paper requisitions and manual posting to AI-driven analytics, automation, and advanced interoperability. The laboratory business continues to face increasing pressure from payer audits, reimbursement cuts, staffing shortages, compliance oversight, and rapidly changing technology requirements. At the same time, laboratories that invest in strong operational controls, experienced revenue cycle management, and scalable LIS platforms are finding opportunities for growth and improved profitability. Jim O’Neill 40 Years Experience in Laboratory Revenue Cycle Management
A Message from Jim: 40 Years of Experience in Billing, Collections, and Laboratory Information Systems Welcome to Laboratory Business Insights, a complimentary newsletter focused on the operational, financial, and technology challenges facing today’s laboratory industry. After four decades working in laboratory billing, collections, revenue cycle management, and LIS implementation, I’ve seen our industry evolve from paper requisitions and manual posting to AI-driven analytics, automation, and advanced interoperability.
A Message from Jim: Over the past year, I’ve had more conversations with laboratory leaders who feel like the rules are changing mid-game. And in many ways, they are. What we’re seeing now isn’t just increased denials or tighter payer scrutiny—it’s a fundamental shift in how revenue is determined.
The Importance of Patient Engagement: Why They - And You - Need It
Learn why patient engagement is a necessity and how you can master it within your practice.
A Message from Jim: As we close the first quarter and look toward the remainder of 2026, the laboratory billing landscape has been reshaped by the Consolidated Appropriations Act and a series of operational shifts that extend far beyond rate adjustments. For laboratory directors, CFOs, and operations leaders, this is not simply regulatory news — it is a strategic inflection point.
Laboratory Revenue Stability in a Post-PAMA Reset Environment A Message from Jim: Clinical laboratories avoided immediate Medicare cuts thismonth — but that does not mean the pressure is gone. The Consolidated Appropriations Act of 2026 delayedPAMA-related payment reductions until January 1, 2027. Labs were facingreimbursement cuts of up to 15% on nearly 800 tests. That pause providestemporary relief.
A Message from Jim O’Neill: National Sales Director, Laboratory Division Whether we’ve connected at AMP, crossed paths on LinkedIn, or this is your first time reading the Lab Digest — welcome. Our goal with each issue is simple: bring forward the operational insights labs can actually use, not just another layer of industry noise.
Your ADSRCM 2025 Year-End Lab Revenue Briefing A Message from Jim: As 2025 draws to a close, it’s clear this has been one of the most financially complex and operationally demanding years the lab industry has seen in over a decade. From payer price compression to the ongoing PAMA uncertainty, mounting denial volumes, and compliance burdens, labs are being pushed to rethink their revenue strategies—and fast. At ADSRCM, our job is to help you make sense of these challenges, find the missed revenue, and build sustainable billing infrastructure that actually works in today’s landscape.